Skip to content

Effects of upper and lower limb exercises on patients after COVID-19.

Effects of a post-Covid-19 cardiopulmonary rehabilitation protocol: a clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-87pw366
Enrollment
Unknown
Registered
2022-03-29
Start date
2021-05-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Experimental group: 20 post COVID-19 will perform a cardiorespiratory exercise protocol (treadmill, respiratory muscle training, upper limb strengthening and lung expansion training). Control group: 2
E02.760.169.063.500.387

Sponsors

Universidade Federal da Paraíba
Lead Sponsor
Universidade Federal da Paraíba
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Both genders; 18 years of age or older; confirmed diagnosis of COVID-19 by RT PCR test; have a computed tomography scan of the chest.

Exclusion criteria

Exclusion criteria: Participants who develop any disabling condition for participation in the study will be excluded.

Design outcomes

Primary

MeasureTime frame
"Expected outcome 1": Assessment of pulmonary function: spirometry will be performed according to the criteria of the American Thoracic Society (ATS) (MILLER et al., 2005). All patients will perform at least three maneuvers, in a sitting position, with a nose clip and attached mouthpiece, they will be instructed to perform maximum inspiration, until the total lung capacity, followed by maximum and continuous forced expiration for a few seconds, until the residual volume. (VR). The forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), FEV1 / FVC ratio, peak expiratory flow and intermediate expiratory flows will be determined (PEREIRA; SATO; RODRIGUES, 2007).

Secondary

MeasureTime frame
"Expected outcome 2": Respiratory muscle function: to assess respiratory muscle function, a computerized electronic device (KH2; PowerBreathe International Ltd. UK) will be used together with a Breathelink feedback. There will be evaluation by means of the maximum inspiratory pressure (IMP) and the resistance of the respiratory musculature. During the test, patients will remain seated with their arms supported and a nose clip to prevent air leakage out of the device. During the PIM assessment, the patient will be instructed to exhale to the residual volume and then perform a maximum inhalation maintained for as long as possible, neglected when less than 1.5 seconds. This evaluation will be carried out from three to a maximum of eight repetitions, seeking variations of less than 10% in the values ??between them. It will be considered the measure of greatest value. Respiratory muscle resistance will be assessed by an incremental load test, where patients will be instructed to perform the greatest number of breaths. An initial load of 10 cmH2O will be standardized for a period of two minutes. Subsequently, the patient will be instructed to rest for one minute and then a new two-minute cycle will be started, adding another 10 cmH20 to the equipment load. The highest load sustained for at least one minute will be considered the value of the sustained PIM. The test will be interrupted if the participant fails the task or if it is determined by the evaluator that the participant is unable to generate the target pressure. In addition, there will be an interruption in the test if the sensation of dyspnea or fatigue is described by the patient as too uncomfortable to tolerate. The IMP will be assessed before (initial IMP) and shortly after the incremental load test (final IMP) to verify the occurrence of muscle fatigue. The division between the final PIM and the initial PIM will be called the fatigue resistance index (IRF). We will consider the occurrence of reduced respirato

Countries

Brazil

Contacts

Public ContactEduardo de França

Universidade Federal da Paraíba

edueriko@hotmail.com(+55) 81988775859

Outcome results

None listed

Source: REBEC (via WHO ICTRP)